Clinical review of sitagliptin: A DPP-4 inhibitor

Journal of Association of Physicians of India

Volumn 61, Issue 9, 2013, Pages 645-649

  Garg, Kamlesh ^a   Tripathi, C D ^a   Kumar, Surinder ^a  

^a SAFDARJUNG HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INCRETIN; PYRAZINE DERIVATIVE; SITAGLIPTIN; TRIAZOLE DERIVATIVE;

ARTICLE; DRUG INTERACTION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; PYRAZINES; TRIAZOLES;

EID: 84883796648     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Pratley RE and Gilbert M. Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor agonists and DPP-4 inhibitiors. The Review of Diabetic Studies 2008;5:73-94.
2. Amori RE, Lau J, Pittas AG. Efficacy and Safety of incretin therapy in type 2 diabetes: Systemic Review and Analysis. JAMA 2007;298:194-206.
3. Gallwitz B. Review of Sitagliptin phosphate: a novel treatment for type 2 diabetes. Vascular Health and Risk Management 2002;3:203-10.
4. Neumiller JJ. Differential chemistry (structure), Mechanism of action, and Pharmacology of GLP-1 receptor agonist and DPP-4 inhibitors. J Am Pharm Assoc 2009;49:16-29.
5. Kim W and Eagan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacological Reviews 2008;60:470-512.
6. Nicolucci A and Rossi MC. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta Biomed 2008;79:184-191.
7. Drucker D, Easley C, Kirkpatrick P. News and analysis. Nature reviews drug discovery 2007;6:109-110.
8. Cherbonnel B, Karasik A, Liu J, Wu M, Menininger G. Efficacy and safety of the Dipeptidyl Peptidase-4 inhibitor Sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43.
9. Beconi MG, Reed JR, Teffera Y, Xia YQ, Kochansky CJ, Liu DQ et al. Disposition of the dipeptidyl peptidase 4 inhibitor Sitagliptin in Rats and Dogs. Drug Metabolism and Disposition 2006;35:525-32.
10. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman DE, Khatami H. Efficacy and safety of the Dipeptidyl Peptidase-4 inhibitor Sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71.
11. Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W et al. Effect of Renal insufficiency on the pharmacokinetics of Sitagliptin, a Dipeptidyl Peptidase-4 inhibitor. Diabetes Care 2007;30:1862-64.
12. Migoya EM, Stevens CH, Bergman AJ, Luo WL, Lasseter KC, Dilzer SC et al. Effect of moderate hepatic insufficiency on the pharmacokinetics of Sitagliptin. Can J Clin Pharmacol 2009;16:165-70.
13. Wesley UV, Tiwari S, Houghton AN. Role of Dipeptidyl Peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int J Cancer 2004;109:855-66.
14. Wesley UV, McGroarty M, Homoyouni A. Dipeptidyl Peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res 2005;65:1325-34.
15. Schwartz F, Entschladen F, Niggemann B, Zaenker KS. DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells. Regulatory Peptides 2006;137:147-55.
16. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the Dipeptidyl Peptidase-4, inhibitor Sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-37.
17. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, and Metformin on Glycaemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87.
18. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and Safety of the dipeptidyl peptidase-4 inhibitor, Sitagliptin, compared with the Sulfonylures, Glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9: 194-205.
19. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and Safety of Dipeptidyl Peptidase-4 inhibitor Sitagliptin added to ongoing Pioglitazone therapy in patients with Type 2 Diabetes: A 24-week, multicentric, randomized double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics 2006;28:1556-68.
20. Hermansen K, Kipnes M, Luo E, Fanurik D, Khataami H, Stein P. Efficacy and Safety of the dipeptidyl peptidase-4 inhibitor, Sitagliptin, in patients with type 2 diabetes inadequately controlled on glimepiride alone or on glimepiride and Metformin. Diabetes Obese Metab 2007;9:733-45.
21. Campbell IW, Day C. Sitagliptin-Enhancing Incretin Action: Sitagliptin. British Journal of Diabetes and Vascular Disease 2007;7:134-39.
22. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008;9:310-22.
23. Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl 4 inhibitors for the treatment of type 2 diabetes: focus on Sitagliptin. Clinical Pharmacology and Therapeutics 2007;81:761-67.
24. Neumiller JJ and Campbell RK. Saxagliptin: a dipeptidyl peptidase 4 inhibitor for the treatment of type 2 diabetes mellitus. Am J Health Syst Pharm 2010;67:1515-25.
25. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause NI. Efficacy and safety of Saxagliptin in combination with metformin compared with Sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.2010; Sept 7 (ePub ahead of print).
26. Andukuri R, Drincic A, Rendell M. Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes, Metabolic syndromes and obesity: Targets and Therapy 2009;2:117-26.
27. Sum L and Maha S. Saxagliptin: A new Dipeptidyl Peptidase-4 inhibitor for type 2 diabetes. Cardiology in Review 2010;18:213-17.